Effect of growth hormone treatment on children with idiopathic short stature and idiopathic growth hormone deficiency.
10.6065/apem.2017.22.2.119
- Author:
Minji IM
1
;
Yong Dae KIM
;
Heon Seok HAN
Author Information
1. Department of Pediatrics, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea. hshan@chungbuk.ac.kr
- Publication Type:Original Article
- Keywords:
Growth hormone;
Idiopathic short stature;
Growth hormone deficiency
- MeSH:
Adult;
Child*;
Growth Hormone*;
Humans;
Insulin-Like Growth Factor Binding Protein 3;
Insulin-Like Growth Factor I;
Medical Records;
Retrospective Studies
- From:Annals of Pediatric Endocrinology & Metabolism
2017;22(2):119-124
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: There are inconsistencies in the results reported in a small number of previous studies into growth hormone (GH) treatment in Korean children with idiopathic short stature (ISS) and idiopathic growth hormone deficiency (IGHD). Thus, the authors retrospectively compared the effects of GH in ISS and IGHD. METHODS: From the medical records of 26 ISS and 30 IGHD children, auxological and biochemical changes including chronologic age (CA), bone age (BA), height standard deviation score (HT-SDS), predicted adult height (PAH), midparental height (MPH), insulin-like growth factor-1 (IGF-1), and insulin-like growth factor binding protein-3 (IGFBP-3) were compared. RESULTS: Before treatment, IGHD group had younger BA, lower BA/CA ratio, and lower IGF-1 level than those in the ISS group. During GH treatment, the levels of IGF-1 and IGFBP-3 were not different. Although annual BA increment was higher in IGHD group, and annual PAH-SDS increment was higher in ISS group, annual HT-SDS increments were not different. Both HT-SDS and PAH-SDS in the ISS group increased significantly until the end of the second year, and then those were not significantly different from MPH-SDS. In the IGHD group, the HT-SDS showed a significant increase till the end of the second year, and the PAH-SDS was not significantly changed at each year, but both HT-SDS and PAH-SDS were not significantly different from MPH-SDS at the end of the third year. CONCLUSION: During GH treatment, both HT-SDS and PAH-SDS approached the genetic target range of MPH-SDS after 2 years in ISS children and 3 years in IGHD children.
